Approximately 30% of patients with both primary and recurrent ovarian serous cancers demonstrate EGFR overexpression.26 Similarly, the FGFR signaling pathway has been shown to be upregulated in the majority of human tumor types.27 The gene discussed is EGFR; the disease is neoplasm.